Pharvaris (NASDAQ:PHVS - Get Free Report) hit a new 52-week low during trading on Thursday . The company traded as low as $14.00 and last traded at $14.85, with a volume of 294 shares. The stock had previously closed at $14.95.
Analysts Set New Price Targets
Separately, JMP Securities increased their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.
View Our Latest Analysis on PHVS
Pharvaris Stock Performance
The company has a 50 day moving average of $16.31 and a 200 day moving average of $18.72. The firm has a market cap of $746.70 million, a P/E ratio of -5.10 and a beta of -2.84.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Pharvaris by 30.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after purchasing an additional 14,838 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Pharvaris during the 4th quarter worth about $853,000. Soleus Capital Management L.P. increased its holdings in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after acquiring an additional 216,483 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Pharvaris in the 4th quarter valued at approximately $152,000. Finally, Octagon Capital Advisors LP lifted its holdings in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after purchasing an additional 157,530 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
